

Appendix 1. Acronyms Used in this Progress Review

A2ALL	Adult-to-Adult Living Donor Liver Transplantation Cohort Study
AACTG	Adult AIDS Clinical Trials Group
AASLD	American Association for the Study of Liver Diseases
AAV	adeno-associated virus vector
ABC	ATP-binding cassette
AFP	alpha-fetoprotein
AIH	autoimmune hepatitis
AIP	acute intermittent porphyria
ALFSG	Adult Acute Liver Failure Study Group
AP-1	activator protein-1
ARC	arthrogryposis-renal dysfunction-cholestasis
ARPKD	autosomal recessive polycystic kidney disease
ATP	adenosine triphosphate
BARC	Biliary Atresia Research Consortium
BMP-4	bone morphogenetic protein-4
BSEP	bile salt export pump
cAMP	adenosine 3',5'-cyclic monophosphate
CAR	constitutive androstane receptor
CB1	cannabinoid receptor 1
cccDNA	covalently closed circular DNA
CDC	Centers for Disease Control and Prevention
CF	cystic fibrosis
CFTR	cystic fibrosis transmembrane regulator
CHF	congenital hepatic fibrosis
CLiC	Cholestatic Liver Disease Consortium
CT	computed tomography
DCP	des-gamma-carboxy prothrombin
DDICC	Digestive Diseases Interagency Coordinating Committee
DHBV	duck hepatitis B virus
DILIN	Drug-Induced Liver Injury Network
EBV	Epstein-Barr virus
EDRN	Early Disease Recognition Network
EPIC3	Evaluation of PegIntron in Control of Hepatitis C Cirrhosis study
EPP	erythropoietic protoporphyria
ER	endoplasmic reticulum
FDA	Food and Drug Administration
FGF	fibroblast growth factor
FXR	farnesoid X receptor
FY	fiscal year
GLP-1	glucagon-like peptide 1
HALT-C	Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis trial
HAV	hepatitis A virus
HBV	hepatitis B virus

HCC	hepatocellular carcinoma
HCIG	hepatitis C immune globulin
HCV	hepatitis C virus
HDV	hepatitis D virus
HEIRS	Hemochromatosis and Iron Overload Screening study
HIV	human immunodeficiency virus
HLA	human leukocyte antigen
HRSA	Health Resources and Services Administration
HURSO	High Dose Ursodiol for Primary Sclerosing Cholangitis study
HVPG	hepatic venous pressure gradient
IFN	interferon
IL	interleukin
IP ₃	inositol 1,4,5-trisphosphate
IRG	initial review group
JAK	janus kinase
JNK	c-Jun N-terminal kinase
LABS	Longitudinal Assessment of Bariatric Surgery
LADR	Low Dose Accelerating Regimen study (of A2ALL)
LCMV	lymphocytic choriomeningitis virus
LXR	liver X receptor
MAPK/ERK	mitogen-activated protein/extracellular signal-regulated kinase
MAVS	mitochondrial antiviral signaling protein
MDR	multi-drug resistance
MELD	Model for End-stage Liver Disease
MRI	magnetic resonance imaging
MRP	multidrug-resistance-associated protein
MSH	melanocyte-stimulating hormone
NAC	N-acetylcysteine
NAFLD	nonalcoholic fatty liver disease
NASH	nonalcoholic steatohepatitis
NASH CRN	Nonalcoholic Steatohepatitis Clinical Research Network
NCCAM	National Center for Complementary and Alternative Medicine
NCI	National Cancer Institute
NCRR	National Center for Research Resources
NHGRI	National Human Genome Research Institute
NHLBI	National Heart, Lung, and Blood Institute
NIAAA	National Institute on Alcohol Abuse and Alcoholism
NIAID	National Institute of Allergy and Infectious Diseases
NIBIB	National Institute of Biomedical Imaging and Bioengineering
NICHD	National Institute of Child Health and Human Development
NIDA	National Institute on Drug Abuse
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS	National Institute of Environmental Health Sciences
NIGMS	National Institute of General Medical Sciences
NIH	National Institutes of Health
NK	natural killer cell

NKT	natural killer T cell
NMR	nuclear magnetic resonance
NO	nitric oxide
NTCP	Na ⁺ /taurocholate co-transporting polypeptide
OATP	organic anion transporter
ODS	Office of Dietary Supplements
OLT HBV	Orthotopic Liver Transplantation for Hepatitis B Study
ORD	Office of Rare Diseases
OST	organic solute transporter
PA	program announcement
PACTG	Pediatric AIDS Clinical Trials Group
PAI-1	plasminogen activator inhibitor-1
PALFSG	Pediatric Acute Liver Failure Study Group
PBC	primary biliary cirrhosis
PELD	Model for Pediatric End-stage Liver Disease
PET	positron-emission tomography
PFIC	progressive familial intrahepatic cholestasis
Peds-C	Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C
PGRN	Pharmacogenetics Research Network
PIVENS	Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis study
PPAR	peroxisome proliferator-activated receptor
PSC	primary sclerosing cholangitis
PSR	phosphatidylserine receptor
PTLD	post-transplant lymphoproliferative disease
PXR	pregnane X receptor
RFA	request for applications
SAMe	S-adenosylmethionine
SBIR	Small Business Innovation Research Program
siRNA	small interfering RNA
SNP	single nucleotide polymorphism
SPLIT	Study of Pediatric Liver Transplantation
SREBP	sterol-regulatory element binding protein
START	STERoids in biliary Atresia Randomized Trial
STAT	signal transducer and activator of transcription
STTR	Small Business Technology Transfer Program
SyNCH	Silymarin in NASH and Chronic Hepatitis C
TONIC	Treatment of Nonalcoholic Fatty Liver Disease in Children trial
TGF	transforming growth factor
TLR	toll like receptor
TNF- α	tumor necrosis factor- α
TNFR1	tumor necrosis factor receptor 1
TPN	total parenteral nutrition
VEGF	vascular endothelial growth factor
Virahep-C	Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C